Redwood Pharma AB (publ) to conduct rights issue

Subscription period 1 June – 20 June 2017

(Units comprising one equity share and one option)


Redwood Pharma Roadshow

13 June, 10:00 AM – Aktielunchen Stockholm, Aktiespararna
Hotel Birger Jarl. Birger Jarlsgatan 61A, 113 53 Stockholm
Sign up here:

13 June, 5:15 PM – Investerarafton,
Volvo Studio. Jussi Björlings Alle 5, Kungsträdgården, 103 91 Stockholm
Sign up here:

12-14 September – Nordic Life Science Days (NLSDays) 2017
Malmömässan. Mässgatan 6, 215 32 Malmö
Sign up here:


Redwood Pharma AB is a company whose mission is to develop new ophthalmic pharmaceutical therapies where there are large and unmet market needs. It has in-licensed, IntelliGel, a proprietary and patented hydrogel drug delivery platform technology that will reduce dosages, dosing-frequency and, thereby, potential systemic toxicities of active pharmaceutical ingredients. The Company’s lead development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women. With an ageing population, DED affects more and more people hindering many in their daily activities such as reading, using a computer and driving an automobile.